Medication info
Excigluem Sustained-release Tablet 5/500 mg

Excigluem Sustained-release Tablet 5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletDapagliflozin›5mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Orange, double convex, rectangular sustained-release film-coated tablet
Packaging
10 tablets/box [10 tablets/PTP x 1], 30 tablets/bottle, 30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202107478 · Approved 2021.11.15 · Insurance code 643309200

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior experience with antidiabetic drug therapy and for whom adequate glycemic control cannot be achieved with monotherapy: When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same dose of metformin the patient was taking or an appropriately equivalent therapeutic dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering agents. Since changes may cause alterations in glycemic control, any changes in treatment for patients with type 2 diabetes should be made under close monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Since metformin is excreted through the kidneys and renal function is more likely to be reduced in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Type 2 diabetes
  • impaired blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used to help control blood sugar levels in adults with type 2 diabetes by combining dapagliflozin and metformin. It can effectively manage blood sugar levels when administered alongside dietary and exercise therapies. It is particularly important for patients who have difficulty controlling their blood sugar and have cardiovascular disease or risk factors to consult with a healthcare professional regarding the potential impacts on cardiovascular events. This medication contributes to the improvement of patients’ health by aiding in safe and systematic blood sugar management.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior experience with antidiabetic drug therapy and for whom adequate glycemic control cannot be achieved with monotherapy: When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same dose of metformin the patient was taking or an appropriately equivalent therapeutic dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering agents. Since changes may cause alterations in glycemic control, any changes in treatment for patients with type 2 diabetes should be made under close monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Since metformin is excreted through the kidneys and renal function is more likely to be reduced in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication helps control blood sugar levels. However, it may rarely cause a serious condition known as lactic acidosis, so caution is warranted. When using this medication, there is a risk of hypoglycemia when taken with insulin or sulfonylureas, so care should be taken. This medication should not be used in patients with severely reduced kidney function, dehydration, serious infections, cardiovascular issues, or acute myocardial infarction. Additionally, pregnant or nursing women, patients with lactose intolerance, and those undergoing dialysis should not take this medication. Before taking the medication, it is essential to check fluid volume and kidney function, especially in elderly patients or those with compromised kidney function. This medication may increase the risk of genital infections or urinary tract infections; hence, if symptoms of infection appear, prompt consultation with a physician is necessary. Hypoglycemic symptoms may occur, so dosage adjustment may be needed when used in combination with insulin or other hypoglycemic agents. While taking this medication, there may be rare side effects such as dizziness, dry mouth, constipation, and back pain; if any unusual symptoms occur, they should be reported. This medication should not be administered to patients with impaired liver function, and alcohol consumption should be avoided due to an increased risk of lactic acidosis. Before surgery or radiologic examinations, this medication should be stopped for a certain period, and only resumed once normal kidney function is confirmed. Vitamin B12 deficiency may occur, so regular monitoring of serum vitamin B12 levels is advisable. In cases of overdose, immediate medical attention should be sought, and this medication should not be used by children or pregnant women. During treatment, caution should be exercised about dizziness when driving or operating machinery, and it should be stored in its original container out of reach of children.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • reduced fluid volume
  • thirst
  • diabetic ketoacidosis
Show 79 more
  • dizziness
  • constipation
  • dry mouth
  • lumbago
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • chest pain
  • thermal burn
  • wrist fracture
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood glucose
  • tendinitis
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinopathy
  • trigger finger
  • asthenia
  • fatigue
  • peripheral edema
  • edema
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • benign prostatic hyperplasia
  • atrial fibrillation
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture and kept at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Orange, double convex, rectangular sustained-release film-coated tablet

Package unit

10 tablets/box [10 tablets/PTP x 1], 30 tablets/bottle, 30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.